Q3-osavuosiraportti
8 päivää sitten‧30 min
0,7306 ILS/osake
Viimeisin osinko
Tarjoustasot
Määrä
Osto
1 600
Myynti
Määrä
108
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
6,95VWAP
Alin
6,78VaihtoMäärä
0,8 146 910
VWAP
Ylin
6,95Alin
6,78VaihtoMäärä
0,8 146 910
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 10.11. | |
| 2025 Q2-osavuosiraportti | 13.8. | |
| 2025 Q1-osavuosiraportti | 14.5. | |
| 2024 Q4-osavuosiraportti | 5.3. | |
| 2024 Vuosiraportti | 5.3. |
Datan lähde: Morningstar, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·10.11.Kamada reports strong results for the third quarter and nine months in 2025, with over 30 percent year-over-year increase in profitability, the company writes in a press release. Revenues for the third quarter of 47.0 million USD, up 13 percent from the previous year, and adjusted EBITDA of 11.7 million USD, up 34 percent from the previous year. Revenues for nine months of 135.8 million USD, up 11 percent from the previous year; adjusted EBITDA of 34.2 million USD, up 35 percent from the previous year. Positive outlook for the rest of 2025 based on the company's product portfolio supports the full-year revenue forecast of 178–182 million USD and adjusted EBITDA of 40–44 million USD. Generated 17.9 million USD in cash from operations during the first nine months of 2025; as of September 30, 2025, the company had 72.0 million USD in available cash. The company continues to focus on advancing business development opportunities to support continued long-term annual double-digit profitable growth. Interim futility analysis of the pivotal Phase 3 InnovAATe clinical study for inhaled AAT therapy will be conducted in the current quarter. Source: https://www.kamada.com/news/kamada-reports-strong-third-quarter-and-nine-month-2025-financial-results-with-over-30-year-over-year-profitability-growth- ·12.8.Kamada reports that the U.S. Food and Drug Administration (FDA) has approved Kamada Plasma’s collection center in Houston, Texas. The approval means the center can begin commercial sales of source plasma at the U.S. facility, which has 50 donor slots and a planned capacity of approximately 50,000 liters per year. The Houston facility is expected to become one of the largest specialty plasma collection centers in the United States. Source: kamada.com/news
- ·20.6.Both business operations and product availability continue as normal despite the situation in the Middle East, Kamada writes in a press release. "While our shipments from Israel may be temporarily affected by the current closure of Israeli airspace, our distribution centers outside of Israel, as well as our partners and distributors worldwide, have a sufficient level of product available, and we see no shortage to meet customer needs," says CEO Amir London. Source: kamada.com
·11.2.The stock is hyped on the YouTube channel Felixandfriends, which is probably why the move was made on Friday.
·11.2. · MuokattuAny of these 63 here who know why or what it was that made KAMADA jump from Friday night 7.2 to Monday morning 10.2? Gape up! Also out of curiosity - where did you first hear about this?
·12.2.Why Friday in particular I'm not sure, but there is a lot of positive news about Kamada on many stock-related websites. I don't remember if Friday was positive for most people? Was it an institution that bought in perhaps - I don't go so deep into the analysis that I check who has bought shares :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
8 päivää sitten‧30 min
0,7306 ILS/osake
Viimeisin osinko
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10.11.Kamada reports strong results for the third quarter and nine months in 2025, with over 30 percent year-over-year increase in profitability, the company writes in a press release. Revenues for the third quarter of 47.0 million USD, up 13 percent from the previous year, and adjusted EBITDA of 11.7 million USD, up 34 percent from the previous year. Revenues for nine months of 135.8 million USD, up 11 percent from the previous year; adjusted EBITDA of 34.2 million USD, up 35 percent from the previous year. Positive outlook for the rest of 2025 based on the company's product portfolio supports the full-year revenue forecast of 178–182 million USD and adjusted EBITDA of 40–44 million USD. Generated 17.9 million USD in cash from operations during the first nine months of 2025; as of September 30, 2025, the company had 72.0 million USD in available cash. The company continues to focus on advancing business development opportunities to support continued long-term annual double-digit profitable growth. Interim futility analysis of the pivotal Phase 3 InnovAATe clinical study for inhaled AAT therapy will be conducted in the current quarter. Source: https://www.kamada.com/news/kamada-reports-strong-third-quarter-and-nine-month-2025-financial-results-with-over-30-year-over-year-profitability-growth
- ·12.8.Kamada reports that the U.S. Food and Drug Administration (FDA) has approved Kamada Plasma’s collection center in Houston, Texas. The approval means the center can begin commercial sales of source plasma at the U.S. facility, which has 50 donor slots and a planned capacity of approximately 50,000 liters per year. The Houston facility is expected to become one of the largest specialty plasma collection centers in the United States. Source: kamada.com/news
- ·20.6.Both business operations and product availability continue as normal despite the situation in the Middle East, Kamada writes in a press release. "While our shipments from Israel may be temporarily affected by the current closure of Israeli airspace, our distribution centers outside of Israel, as well as our partners and distributors worldwide, have a sufficient level of product available, and we see no shortage to meet customer needs," says CEO Amir London. Source: kamada.com
- ·11.2.The stock is hyped on the YouTube channel Felixandfriends, which is probably why the move was made on Friday.
- ·11.2. · MuokattuAny of these 63 here who know why or what it was that made KAMADA jump from Friday night 7.2 to Monday morning 10.2? Gape up! Also out of curiosity - where did you first hear about this?·12.2.Why Friday in particular I'm not sure, but there is a lot of positive news about Kamada on many stock-related websites. I don't remember if Friday was positive for most people? Was it an institution that bought in perhaps - I don't go so deep into the analysis that I check who has bought shares :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1 600
Myynti
Määrä
108
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
6,95VWAP
Alin
6,78VaihtoMäärä
0,8 146 910
VWAP
Ylin
6,95Alin
6,78VaihtoMäärä
0,8 146 910
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 10.11. | |
| 2025 Q2-osavuosiraportti | 13.8. | |
| 2025 Q1-osavuosiraportti | 14.5. | |
| 2024 Q4-osavuosiraportti | 5.3. | |
| 2024 Vuosiraportti | 5.3. |
Datan lähde: Morningstar, Quartr
Q3-osavuosiraportti
8 päivää sitten‧30 min
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 10.11. | |
| 2025 Q2-osavuosiraportti | 13.8. | |
| 2025 Q1-osavuosiraportti | 14.5. | |
| 2024 Q4-osavuosiraportti | 5.3. | |
| 2024 Vuosiraportti | 5.3. |
Datan lähde: Morningstar, Quartr
0,7306 ILS/osake
Viimeisin osinko
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10.11.Kamada reports strong results for the third quarter and nine months in 2025, with over 30 percent year-over-year increase in profitability, the company writes in a press release. Revenues for the third quarter of 47.0 million USD, up 13 percent from the previous year, and adjusted EBITDA of 11.7 million USD, up 34 percent from the previous year. Revenues for nine months of 135.8 million USD, up 11 percent from the previous year; adjusted EBITDA of 34.2 million USD, up 35 percent from the previous year. Positive outlook for the rest of 2025 based on the company's product portfolio supports the full-year revenue forecast of 178–182 million USD and adjusted EBITDA of 40–44 million USD. Generated 17.9 million USD in cash from operations during the first nine months of 2025; as of September 30, 2025, the company had 72.0 million USD in available cash. The company continues to focus on advancing business development opportunities to support continued long-term annual double-digit profitable growth. Interim futility analysis of the pivotal Phase 3 InnovAATe clinical study for inhaled AAT therapy will be conducted in the current quarter. Source: https://www.kamada.com/news/kamada-reports-strong-third-quarter-and-nine-month-2025-financial-results-with-over-30-year-over-year-profitability-growth
- ·12.8.Kamada reports that the U.S. Food and Drug Administration (FDA) has approved Kamada Plasma’s collection center in Houston, Texas. The approval means the center can begin commercial sales of source plasma at the U.S. facility, which has 50 donor slots and a planned capacity of approximately 50,000 liters per year. The Houston facility is expected to become one of the largest specialty plasma collection centers in the United States. Source: kamada.com/news
- ·20.6.Both business operations and product availability continue as normal despite the situation in the Middle East, Kamada writes in a press release. "While our shipments from Israel may be temporarily affected by the current closure of Israeli airspace, our distribution centers outside of Israel, as well as our partners and distributors worldwide, have a sufficient level of product available, and we see no shortage to meet customer needs," says CEO Amir London. Source: kamada.com
- ·11.2.The stock is hyped on the YouTube channel Felixandfriends, which is probably why the move was made on Friday.
- ·11.2. · MuokattuAny of these 63 here who know why or what it was that made KAMADA jump from Friday night 7.2 to Monday morning 10.2? Gape up! Also out of curiosity - where did you first hear about this?·12.2.Why Friday in particular I'm not sure, but there is a lot of positive news about Kamada on many stock-related websites. I don't remember if Friday was positive for most people? Was it an institution that bought in perhaps - I don't go so deep into the analysis that I check who has bought shares :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1 600
Myynti
Määrä
108
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
6,95VWAP
Alin
6,78VaihtoMäärä
0,8 146 910
VWAP
Ylin
6,95Alin
6,78VaihtoMäärä
0,8 146 910
Välittäjätilasto
Dataa ei löytynyt